SEC Form 8-K Summary
Business Context and Reporting Period
MeiraGTx Holdings plc filed a Form 8-K dated September 22, 2026, with the report signed September 23, 2026. The filing concerns a board appointment and related Regulation FD disclosure, not periodic financial results.
- Registrant: MeiraGTx Holdings plc, a Cayman Islands company.
- Trading symbol: MGTX on the Nasdaq Global Select Market.
- Principal executive office: New York, New York.
Financial Metrics and Capital Position
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, valuation, or other financial operating metrics. It is not a quarterly or annual earnings filing.
Material Changes
- Effective September 23, 2026, the Board appointed Alan M. Sebulsky as a Class I director.
- His term expires at the Company’s 2028 annual meeting of shareholders, subject to the election and qualification of a successor.
- Mr. Sebulsky was appointed to the Science and Technology Committee.
- He has served as Managing Member of Apothecary Capital LLC since April 2026 and previously was a Partner and Portfolio Manager at Adage Capital Management, LP.
- He is currently a director of Parabilis Medicines, Inc. and has prior biopharmaceutical and healthcare investment experience.
Compensation, Outlook, Risks, and Unusual Items
- Mr. Sebulsky will be eligible for compensation under the Company’s non-employee director compensation program.
- The Company expects him to enter into its standard director and officer indemnification agreement.
- The filing states that there are no related-party transactions between the Company and Mr. Sebulsky and that he was not selected pursuant to an arrangement or understanding with another person.
- The Company issued a September 23, 2026 press release announcing the appointment. The Regulation FD disclosure, including the exhibit, is not deemed filed for purposes of Section 18 of the Exchange Act, except as expressly incorporated by reference.
Important Facts to Verify
- Confirm the effective date of the appointment and the Class I term through the 2028 annual meeting.
- Review Exhibit 99.1 for the complete press release and any additional biographical or governance commentary.
- Verify the director compensation and indemnification terms under the Company’s current standard arrangements.
- Consult the Company’s latest periodic filing for current financial results, liquidity, debt, cash runway, operating risks, and development-program updates, none of which are provided in this 8-K.